I'm not at all in a hurry for funding news. The co. has indicated in various ways that it is not a problem. The longer CYGX can go without outside funding, the more they can get for the products in their pipeline. As in today's press release, they seem to be able to line up research agreements as needed for their various therapeutics, and this is due to the status and quality of the company's scientists and business leaders.
Also, re today's PR, any speculation from our bio people as to the method of delivery for a sepsis supressant?
News 
Market Data 
Discover 
AI
